The estimated Net Worth of Ely Benaim is at least $4.17 million dollars as of 3 August 2022. Ely Benaim owns over 5,959 units of NovoCure Ltd stock worth over $494,019 and over the last 10 years he sold NVCR stock worth over $3,672,276. In addition, he makes $0 as Chief Medical Officer at NovoCure Ltd.
Ely has made over 19 trades of the NovoCure Ltd stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 5,959 units of NVCR stock worth $439,357 on 3 August 2022.
The largest trade he's ever made was selling 5,959 units of NovoCure Ltd stock on 3 August 2022 worth over $439,357. On average, Ely trades about 1,616 units every 51 days since 2015. As of 3 August 2022 he still owns at least 28,672 units of NovoCure Ltd stock.
You can see the complete history of Ely Benaim stock trades at the bottom of the page.
Dr. Ely Benaim M.D. serves as Chief Medical Officer of the Company. He has been our Chief Medical Officer since 2019. Dr. Benaim previously served as Chief Medical Officer for Rexahn Pharmaceuticals from 2015 to 2019, where he was responsible for leading clinical development programs and providing strategic and clinical guidance. Prior to joining Rexahn, he was chief medical officer and senior vice president of regulatory affairs at BERG Health from 2013 to 2015. From 2011 to 2013, Dr. Benaim was senior director, clinical research and global clinical lead for Millennium Pharmaceuticals Inc./Takeda Pharmaceuticals Company. From 2007 to 2010, he was vice president, clinical affairs for Sangamo BioSciences. Dr. Benaim received his M.D. from the Universidad Central de Venazuela, Caracas, and completed his pediatric residency training at the University of South Florida. Dr. Benaim completed fellowships in pediatric oncology and bone marrow transplantation at St. Jude's Children's Research Hospital.
Ely Benaim is 59, he's been the Chief Medical Officer of NovoCure Ltd since 2019. There are 11 older and 12 younger executives at NovoCure Ltd. The oldest executive at NovoCure Ltd is Prof. Yoram Palti, 83, who is the Founder & CTO.
Ely's mailing address filed with the SEC is C/O NOVOCURE INC.,, 1550 LIBERTY RIDGE DRIVE, SUITE 115, WAYNE, PA, 19087.
Over the last 9 years, insiders at NovoCure Ltd have traded over $237,132,855 worth of NovoCure Ltd stock and bought 164,174 units worth $2,198,429 . The most active insiders traders include Asaf Danziger, William Fwfd Ventures Fund ... et Michael J. Ambrogi. On average, NovoCure Ltd executives and independent directors trade stock every 7 days with the average trade being worth of $853,350. The most recent stock trade was executed by Ashley Cordova on 2 August 2024, trading 688 units of NVCR stock currently worth $13,856.
we are a commercial-stage oncology company developing a novel, proprietary therapy called tumor treating fields, or ttfields, for the treatment of solid tumor cancers. we count on the contributions of our talented team members who are committed to improving the lives of cancer patients. here at novocure, cancer patients and their families are – and have always been – at the core of our mission. we expect our colleagues to excel, and in return, we invest in their professional growth and personal well-being. we seek high performers who thrive in fast-paced environments and are inspired by making a difference in cancer care. we offer employment opportunities in the u.s., europe and asia.
NovoCure Ltd executives and other stock owners filed with the SEC include: